Author

P. Lovalenti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Deshpande· 2 shared A. Loos· 2 shared C. Ye· 2 shared J. J. Kobie· 2 shared J. Woo· 2 shared J.-G. Park· 2 shared L. Martinez-Sobrido· 2 shared M. Basu· 2 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Deshpande

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

M. S. Piepenbrink, J.-G. Park, A. Deshpande, A. Loos, C. Ye, M. Basu, S. Sarkar, D. Chauvin, J. Woo, P. Lovalenti, N. B. Erdmann, P. A. Goepfert, V. L. Truong, R. A. Bowen, M. R. Walter, , J. J. Kobie

This study identifies a potent universal coronavirus neutralizing monoclonal antibody, 1249A8, effective against multiple variants and demonstrating therapeutic activity through intranasal administration.

bioRxiv · Mar 5, 2022 · PreprintImmunology

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

M. S. Piepenbrink, J.-G. Park, F. Oladunni, A. Deshpande, M. Basu, S. Sarkar, A. Loos, J. Woo, P. Lovalenti, D. Sloan, C. Ye, K. Chiem, N. B. Erdmann, P. A. Goepfert, V. L. Truong, , J. J. Kobie

This study evaluates an inhaled monoclonal antibody against SARS-CoV-2 in hamsters, showing reduced viral burden and lung pathology with low-dose inhalation.

bioRxiv · Oct 14, 2020Immunology